Claims for Patent: 10,588,983

Summary for Patent: 10,588,983

Title:	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
Abstract:	The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (Georgetown, KY), Frost; Gregory I. (Palm Beach, FL)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	15/904,247
Patent Claims:	1. A method for modulating the immune system in a subject, comprising subcutaneously administering to a subject immune globulin (IG) and a soluble hyaluronidase to enhance the immune system of the subject, wherein: the soluble hyaluronidase is a soluble neutral active human hyaluronidase glycoprotein (sHASEGP): the hyaluronidase is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the hyaluronidase polypeptide: the hyaluronidase polypeptide does not comprise the complete sequence of amino acids set forth in SEQ ID NO: 1; and the hyaluronidase polypeptide consists of: (i) a contiguous sequence of amino acid residues contained within SEQ ID NO: 1 that includes at least amino acids 36-464 of SEQ ID NO: 1, wherein the polypeptide is truncated within the C-terminus of SEQ ID NO: 1 at a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482, 483 and 494 of SEQ ID NO: 1; or (ii) a sequence of amino acid residues that has at least 95% amino acid sequence identity with a sequence of amino acids set forth in (i). 2. The method of claim 1, wherein the IG and soluble hyaluronidase are administered separately. 3. The method of claim 1, wherein the IG and soluble hyaluronidase are administered in a single composition. 4. The method of claim 1, wherein the hyaluronidase has a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ IID NO: 1. 5. The method of claim 1, wherein: (i) the hyaluronidase consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-48 1, 36-482, or 36-483 of SEQ ID NO: 1; or (ii) the hyaluronidase contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-48 1, 36-482, or 3 6-483 of SEQ ID NO: 1, whereby the amino acid-substituted hyaluronidase consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1. 6. The method of claim 1, wherein the soluble hyaluronidase has a C-terminal amino acid residue selected from among 479, 480, 481 and 482 of SEQ ID NO: 1. 7. The method of claim 1, wherein the hyaluronidase contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-48 1, 36-482, or 36-483 of SEQ ID NO: 1, whereby the amino acid-substituted hyaluronidase consists of a sequence of amino acids that has at least 97% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-48 1, 36-482, or 36-483 of SEQ ID NO: 1. 8. The method of claim 1, wherein the hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% sequence identity with residues 36-483 of SEQ ID NO: 1. 9. The method of claim 1, wherein the hyaluronidase is modified with a polymer. 10. The method of claim 9, wherein the polymer is PEG or dextran.

Details for Patent 10,588,983

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2025-02-23
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2025-02-23
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2025-02-23
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2025-02-23
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	05/21/2004		2025-02-23